Dementia trials and dementia tribulations: Methodological and analytical challenges in dementia research

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Ritchie, Craig W ^a   Terrera, Graciela Muniz ^b   Quinn, Terence J ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; COGNITION; DEMENTIA; DEMENTIA ASSESSMENT; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; METHODOLOGY; MINI MENTAL STATE EXAMINATION; NEUROPATHOLOGY; NONHUMAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW;

EID: 84928114663     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0113-6     Document Type: Review

References (58)

1. Luengo-Fernandez R, Leal J, Gray AM. UK research expenditure on dementia, heart disease, stroke and cancer: Are levels of spending related to disease burden. Eur J Neurol. 2012;19:149-54.
2. Stuss DT, Levine B. The dementias: nosological and clinical factors related to diagnosis. Brain Cogn. 1996;31:99-113.
3. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger- Gateau P, et al. Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol. 2010;9:1118-27.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013.
5. World Health Organization. ICD-10 International Statistical Classification of Diseases and Related Health Problems. 10th ed. New York: World Health Organization; 2008.
6. Clark LA, Watson D, Reynold S. Diagnosis and classification of psychopathology challenges to the current system and future directions. Annu Rev Psychol. 1995;46:121-53.
7. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Ageing-Alzheimers Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-92.
8. Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ. Vascular risk factors and Alzheimer's disease: Are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimer's Res Ther. 2012;4:1.
9. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197-204.
10. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66:200-8.
11. Sonnen JA, Santa Cruz K, Hemmy LS, Woltjer LS, Leverenz JB, Montine KS, et al. Ecology of aging human brain. Arch Neurol. 2011;68:1049-56.
12. Hernandez AV, Steyerberg EW, Habbema JDF. Covariate adjustment in randomised controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements. J Clin Epidemiol. 2004;57:454-60.
13. Feldman A, Rizzuto D, Narasimhalu K, Dahl A, Johansson A, Gregorio M, et al. Validity of dementia diagnoses in two Swedish health registers. Alzheimers Dement. 2012;8:493.
14. Jackson TA, Wilson D, Sheehan B. Screening for dementia in general hospital inpatients: A systematic review and meta-analysis of available instruments. Age Ageing. 2013;42:689-95.
15. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: A comprehensive review. J Am Geriatr Soc. 1992;40:922-35.
16. Lees R, Fearon P, Harrison JK, Broomfield NM, Quinn TJ. Cognitive and mood assessment in stroke research: focused review of contemporary studies. Stroke. 2012;43:1678-80.
17. Lees R, Broomfield N, Quinn TJ. Questionnaire assessment of usual practice in stroke cognitive assessment across Scottish Stroke Units. Disability Rehabil. 2014;36:339-43.
18. Ferris SH, Lucca U, Mohs R, Dubois B, Wesnes K, Erzigkeit H. Objective psychometric tests in clinical trials of dementia drugs. Alzheimer Dis Assoc Disord. 1997;11:34-8.
19. Quinn TJ, Fearon P, Noel-Storr AH, Young C, McShane R, Stott DJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations. Cochrane Database Syst Rev. 2014;4, CD010079.
20. Davis DHJ, Creavin ST, Noel-Storr AH, Quinn TJ, Smailagic N, Hyde C, et al. Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementias: A generic protocol for cross-sectional and delayed-verification studies. Cochrane Database Syst Rev. 2013;CD010460.
21. US Food and Drug Administration. Alzheimer's disease: Developing Drugs for the Treatment of Early Stage Disease. Draft guidance. Silver Spring, MD: US Department of Health and Human Services FDA, Center for Drug Evaluation and Research; 2013.
22. Ferris S. Report of the working group on clinical global measures. Position paper from the International Working group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11:8-18.
23. Bond J. Quality of life for people with dementia: Approaches to the challenge of measurement. Ageing Soc. 1999;19:561-79.
24. McMurdo ME, Roberts H, Parker S, Wyatt N, May H, Goodman C, et al. Improving recruitment of older people to research through good practice. Age Ageing. 2011;40:659-65.
25. Bird TD. Genetic aspects of Alzheimer's disease. Genet Med. 2008;10:321-9.
26. Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Brteler M, et al. Advances in the prevention of Alzheimer's disease and dementia. J Internal Med. 2014;275:229-50.
27. Van Dam D, De Deyn PP. Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol. 2011;164:1285-300.
28. Van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7:e1000245.
29. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF. Modelling age-specific risk: Application to dementia. Stat Med. 1998;17:1973-88.
30. Sliwinksi MJ, Hofer SM, Hall C, Bushke H, Lipton RB. Modelling memory decline in older adults. Psychol Ageing. 2003;18:658-71.
31. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics. 2000;1:465-80.
32. Hall BC, Ying J, Kuo L, Sliwinsli M, Buschke H, Katz M, et al. Estimate of bivariate measurements having different change points, with application to cognitive ageing. Stat Med. 2001;20:3695-714.
33. Van den Hout A, Muniz Terrera G, Matthews FE. Smooth random change point models. Stat Med. 2011;30:599-610.
34. Duffy L, Gajree S, Langhorne P, Stott DJ, Quinn TJ. Reliability (inter-rater agreement) of the Barthel Index for assessment of stroke survivors: systematic review and meta-analysis. Stroke. 2013;44:462-8.
35. Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment. J Neurol Neurosurg Psychiatry. 2006;77:429-38.
36. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Int Med. 2004;256:183-94.
37. McArthur KS, Johnson PC, Quinn TJ, Higgins P, Langhorne P, Walters MR, et al. Improving the efficiency of stroke trials: feasibility and efficacy of group adjudication of functional endpoints. Stroke. 2013;44:3422-8.
38. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica Scand. 2009;119:252-65.
39. Noel-Storr A, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P, et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimers Dement. 2013;9:e96-105.
40. Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2014;CD008782.
41. Richard E, Schmand B, Eikelenboom P, Westendorp RG, Van Gool WA. The Alzheimer myth and biomarker research in dementia. J Alzheimers Dis. 2012;31:S203-940.
42. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled. Ann Int Med. 1996;125:605-13.
43. Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis. 2011;26:627-45.
44. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. Lancet. 2012;380:1441-3.
45. Ritchie K, Carrière I, Ritchie CW, Dufouil C, Dartigues JF, Berr C, et al. Can we design population prevention programs to reduce dementia incidence? A simulation of the impact of removal of specific risk factors. BMJ. 2010;341:c3885.
46. Richard E, Andrieu S, Solomon A, Mangialasche F, Ahtiluoto S, van Charante EPM, et al. Methodological challenges in designing dementia prevention trials - The European Dementia Prevention Initiative (EDPI). J Neurol Sci. 2012;322:64-70.
47. Ritchie CW, Wells K, Ritchie K. The PREVENT research programme - A novel research programme to identify and manage midlife risk for dementia: The conceptual framework. Int Rev Psychiatry. 2013;25:748-54.
48. Lincoln P, Fenton K, Alessi C, Prince M, Brayne C, Wortmann M, et al. The Backfriars Consensus on brain health and dementia. Lancet. 2014;383:1805-6.
49. Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013;382:1405-12.
50. Dementias Platform UK. http://www.mrc.ac.uk/research/facilities/dementiasresearch-platform/.
51. About EMIF-Alzheimer's disease. http://www.emif.eu/emif-ad/about-emifalzheimers-disease.
52. Ali M, Bath PM, Curram J, Davis SM, Diener HC, Donnan GA, et al. The virtual international stroke trials archive. Stroke. 2007;38:1905-10.
53. Quinn TJ, Dawson J, Lees JS, Chang TP, Walters MR, Lees KR, et al. Time spent at home poststroke: 'home-time' a meaningful and robust outcome measure for stroke trials. Stroke. 2008;39:231-3.
54. White L, Samll BJ, Petrovitch H. Recent clinic-pathological research on the causes of dementia in late life: update from the Honolulu-Asia aging study. J Geriatr Psychiatry Neurol. 2005;18:224-7.
55. Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo MC, Cummings J, et al. E. U./U.S. CTAD task force on Alzheimer's trial populations. 2014. J Prevention Alzheimer's Dis. 2014;1:110-6.
56. Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum S, et al. Reporting standards for studies of diagnostic test accuracy in Alzheimer's disease and dementia: The STARDdem (STAndards for the Reporting of Diagnostic accuracy studies-dementia) initiative. Neurology. 2014;83:364-73.
57. McClearn GE, Johansson B, Berg S, Pedersen NL, Ahern F, Petrill SA, et al. Substantial genetic influence on cognitive abilities in twins 80 or more years old. Science. 1997;276:1560-3.
58. Hall CB, Lipon RB, Sliwinski M, Stewart WF. A change point model for estimating the onset of cognitive decline in Alzheimer's disease. Stat Med. 2000;19:1555-66.